Prosensa Strengthens its Management Team and Supervisory Board with Key Appointments

Prosensa Strengthens its Management Team and Supervisory Board with Key Appointments  Preparing for anticipated launch of lead compound for DMD  Leiden, The Netherlands, June 30, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today announced the appointment of Willem W. van Weperen to the new position of chief commercial officer and the addition of Dr. Annalisa Jenkins to its Supervisory Board.  With more than two  decades of experience  at Genzyme and  GSK and his  recent  leadership of Dutch to-BBB as CEO, Mr. van Weperen brings significant business operational and commercial expertise to Prosensa in advance of an  anticipated  launch of the company's first product  for the treatment of Duchenne  muscular  dystrophy (DMD).   Hans Schikan, CEO of Prosensa said, "We expect Willem to play a critical  role  at Prosensa as  we move from  a research  and development stage  company to  a  commercial organization. His knowledge and experience will be invaluable as we build the  infrastructure  to support  the  anticipated launch  of  our  first  product for treating boys with DMD."  Prior to his role at  to-BBB, Mr. van Weperen spent  15 years at Genzyme in  a  number of senior management  and commercial positions at  both a national  and  international level. He joined Genzyme in  1994 as medical affairs manager  in  Europe. Subsequently, he worked as Area Manager Therapeutics for the  Benelux,  responsible for  sales  and marketing  of  Genzyme's orphan  disease  products  following which he  took on the  role as European  Marketing Director for  the  Company's LSD/Thyrogen products. Since 2003, he assumed global  responsibility  for marketing in the rare genetic disease business unit in Genzyme's worldwide headquarters in Cambridge,  MA. Most  recently, he  led Genzyme's  Netherlands  organization in Naarden. At Genzyme, he oversaw and significantly contributed to  several  global  launches  of  products  in  the  company's  rare  disease  portfolio.  "I'm thrilled to be joining Prosensa at such an exciting and pivotal time  for  the company and look forward to applying my expertise in commercializing  rare  disease drugs to  potentially launching  one of  the first  products to  treat  DMD," said Mr. van Weperen.  Dr. Jenkins joins  Prosensa's Supervisory  Board with  more than  25 years  of  experience in the healthcare sector. In her most recent role as Head of Global Research and Development and Executive  Vice President at Merck Serono,  which  she has  held since  October 2013,  she was  responsible for  building  global  development,   research   and   medical   capabilities,   spanning   research,  development,  global  regulatory  and  clinical  development  in  addition  to  medical  affairs  and  patient  access.  She  joined  the  company  in  2011,  previously serving as Executive Vice President Global Development and Medical. Prior to joining Merck  Serono, Dr. Jenkins held  various regional and  global  roles with  Bristol-Myers Squibb  since  1997, most  recently as  Senior  Vice  President, Global Medical Affairs.  "We are delighted  to welcome  Annalisa to Prosensa's  Supervisory Board.  Her  extensive experience in research and clinical development and medical  affairs  for Merck Serono and Bristol Myers  Squibb, which are amongst the top  pharma  companies in the  world, will bring  valuable insights  to us as  we take  the  company to the next level," said David Mott, Chairman of the Supervisory Board at Prosensa.  Dr. Jenkins began her career as a Medical Officer with the British Royal  Navy  after graduating  in  Medicine  from St.  Bartholomew's  Hospital  London  and  training in Cardiovascular Medicine in the UK National Health Service.  "I am excited to join Prosensa at such a significant moment in the company's history and look forward to working alongside a world-class team with exceptional leadership in rare diseases," saidDr. Jenkins. "With such an extensive research and development pipeline in DMD, I hope to integrate my expertise in global R&D as Prosensa continues to advance its portfolio of innovative exon-skipping technology."  The appointment of Dr. Annalisa Jenkins will be subject to shareholders' approval at the next shareholders' meeting, scheduled for August 20, 2014.  Notes to editors  About Prosensa Holding N.V.  Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy (DMD), myotonic dystrophy and Huntington's disease.  Prosensa's current portfolio includes six compounds for the treatment of DMD, all of which have received orphan drug status in the United States and the European Union. The compounds use an innovative technique called exon-skipping to provide a personalized medicine approach to treat different populations of DMD patients. www.prosensa.com  CONTACT: Celia Economides          Prosensa Holding N.V.          Sr Director IR & Corporate Communications          c.economides@prosensa.nl  Prosensa Holding B.V. Logo  
Press spacebar to pause and continue. Press esc to stop.